Arsenal Capital Partners Acquires Best Value Healthcare

Arsenal Capital Partners

November 17, 2020

New York, November 17, 2020 – Arsenal Capital Partners (“Arsenal”), a private equity firm that specializes in investments in healthcare and specialty industrial companies, has acquired Best Value Healthcare LLC (“Best Value”) in partnership with its founders:  Raj Naik, M.D., Kimberly Ficocelli, and Dillon Moore.  Best Value is a leading primary care platform focused on Medicare Advantage and operating in Central and South Florida.  The terms of the transaction were not disclosed.

Arsenal’s investment in Best Value reflects the firm’s interest in investing in the value-based primary care market, a large and fast-growing care provision segment uniquely positioned to drive significant value across key healthcare stakeholder groups: patients, physicians, and payers.  Best Value represents a compelling investment given its scale, reputation for high-quality clinical care, focus on advancing value-based care competency, strong payer relationships, experienced management team, and opportunity to realize multiple avenues of organic and inorganic growth.

Mike Bernstein, Operating Partner of Arsenal, said, “After evaluating many of the leading primary care practices in the market, we selected Best Value as the ideal platform for what we plan to build into a best-in-class, value-based primary care organization, serving seniors in partnership with the major Medicare Advantage payers.”

John DiGiovanni, Investment Partner of Arsenal, said, “High-quality and value-based primary care is critical to ensuring greater efficiency and innovation across care provision and better outcomes for patients.  Best Value’s founders have built a leading primary care provider with an excellent clinical reputation.  We look forward to partnering with the team to continue to expand the reach of this platform.”

Dr. Rajankumar Naik, Co-Founder of Best Value, said, “We are excited to be partnering with the Arsenal team, which has an extensive history of investing in the healthcare space.  We are confident that this strategic relationship will enhance Best Value’s ability to serve the growing need for patient-focused and outcomes-oriented primary care.

Guggenheim Securities, LLC served as financial advisor to Best Value.  Macquarie Capital Inc. served as financial advisor to Arsenal.

About Best Value Healthcare LLC:

Headquartered in the Tampa Bay area, Best Value is a patient-centered, physician-led, and population health-focused healthcare company.  Founded and led by physicians, Best Value’s team of healthcare providers and support service professionals share a revolutionary vision for delivering patient care in Florida with passion and purpose.  Best Value creates a direct path to improving outcomes, reducing costs, and enhancing healthcare experiences.  For more information, visit www.bestvaluehealthcare.com.

About Arsenal Capital Partners: 

Arsenal is a leading private equity firm that specializes in investments in middle‐market healthcare and specialty industrials companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, has completed more than 200 platform and add-on investments, and has achieved more than 30 realizations. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value‐add.  For more information, please visit www.arsenalcapital.com.

Categories: News

Tags:

KKR Partners with Duke Rohlen to Create Medical Device Platform

KKR

November 17, 2020

MENLO PARK, Calif.–(BUSINESS WIRE)– KKR, a leading global investment firm, and Duke Rohlen, a 20-year medical device veteran, today announced the formation of Zeus Health (“Zeus”), a $100 million platform focused on investing in and operating a portfolio of emerging medical device companies.

Zeus marks the continuation of a long-standing relationship between KKR and Mr. Rohlen. Throughout his career, Mr. Rohlen has successfully led, grown and exited multiple medical device companies, including alongside KKR. In 2016, KKR invested in Spirox, an ENT-focused medical device company led by Mr. Rohlen as CEO. Spirox was sold to Entellus Medical in 2017, and the combined business was sold to Stryker shortly thereafter in 2018. In 2017, KKR and Mr. Rohlen formed Ajax Health, a medical device platform company whose primary asset EpiX Therapeutics was sold to Medtronic in 2019.

“We are excited to have the opportunity to work with Duke and his team again, now for the third time following our previous success with Ajax Health and Spirox. Duke is a proven leader in the medical device field, as are his team of industry and operational experts. We look forward to working together to identify and scale much-needed next-generation medical technologies,” said Ali Satvat, Global Head of KKR Health Care Strategic Growth and Co-Head of Health Care within KKR’s North America Private Equity platform.

“With the formation of Zeus Health, I am thrilled to further deepen my relationship with KKR, whose unmatched reputation, scale and depth of health care expertise will continue to open new doors for us as we look to bring innovative medical devices to patients in need,” said Mr. Rohlen.

For KKR, the investment in Zeus Health is being funded through the firm’s Health Care Strategic Growth Fund, which is focused on investing in high-growth health care-related companies for which KKR can be a unique partner in helping reach scale. KKR has established a strong track record of supporting health care companies, having invested approximately $14 billion across the sector since 2004.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, credit and real assets, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Media Contact:
Cara Major or Miles Radcliffe-Trenner
212-750-8300
media@kkr.com

Source: KKR

Categories: News

Tags:

Upfront Healthcare Raises $11.5 Million in Series B Funding Round Led by Baird Capital and Co-Led by LRVHealth

Baird Capital

Investment, platform expansion and new client growth highlight the demand for a cohesive and personalized patient experience.

CHICAGO—(November 17, 2020)—Upfront Healthcare, a leading omnichannel communication and patient engagement platform, raised $11.5 million in a Series B funding round, led by new investor Baird Capital and co-led by existing investor LRVHealth, along with participation from series A investors Echo Health Ventures, Nashville Capital Network, Hyde Park Ventures and Martin Ventures. Upfront has received $21.5 million in financing to date.

Founded in 2016, Upfront has built a foundational platform designed to grow with health system clients and their ever-changing needs. Upfront provides extensible patient solutions that continuously guide and motivate all patients to complete necessary care at the most appropriate site or with the most applicable service. Upfront engages patients across multiple channels, presenting personalized, curated content and culturally relevant information. Under the hood, Upfront is powered by a library of data connectors, integrated machine learning capabilities, and an enterprise orchestration engine.

“We are extremely excited to partner with Upfront’s talented team to help drive the company’s continued growth and impact on care delivery and patient outcomes for its clients,” said Jim Pavlik, Partner with Baird Capital. “The combination of Upfront’s deep industry expertise and robust platform capabilities is critical and timely as health systems increasingly adopt digital solutions to better navigate the complex and rapidly changing care ecosystem for their patients.”

Patient confusion, frustration and distrust peaked over the last twelve months with the expansion of health system sites of care and services and the COVID-19 pandemic. As a result, the demand for Care Traffic Control solutions that can transform a fragmented collection of services into a coherent, well-designed ecosystem drove rapid growth, doubling Upfront’s revenue year over year. In addition, health systems accelerated their digital health strategies to engage patients and regain trust, increasing the adoption of Upfront at existing clients more than 10x. The additional funds will support the implementation of these evolving health system and patient needs, accelerate the product roadmap and expand sales and marketing.

Co-Founders Ben Albert and Carrie Kozlowski drew on their decades of healthcare technology experience, entrepreneurial drive and Kozlowski’s extensive clinical and care management background to start Upfront. They continue to rely on those strengths to scale the company and deliver proven strategic and operational guidance to their growing list of health system clients.

“We set out more than four years ago to help patients navigate the complexities of the healthcare system by delivering a cohesive and frictionless experience, and we have made great progress toward that goal,” said Albert, Upfront’s CEO. “We are excited to partner with leading investor Baird Capital and eager to work together to continue to invest in our platform to make a larger impact for patients and providers.”

###

About Upfront

Upfront’s Care Traffic Control platform proactively reassures and directs patients to the safest and most relevant care options within the health system. Using advanced analytics, personalized content and strategic calls-to-action, Upfront aligns patient care needs with health system resources through a 1:1 digital experience based on deep healthcare operations and patient engagement experience. With Upfront, more patients will book and complete necessary care, use the most appropriate site of care, enroll in care coordination services, successfully navigate a care journey or transition, and understand how to stay safe in unusual conditions. To learn more, visit UpfrontHealthcare.com.

About Baird Capital

Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 310 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit www.BairdCapital.com.

 

Upfront Media Contact:
Kylie Barrie
(847) 989-8050
kbarrie@upfronthealthcare.com

Baird Capital Media Contact
Rachel Kern
(414) 298-5101
RKern@rwbaird.com

Categories: News

Tags:

Troy Medicare announces $10M Series B led by AXA Venture Partners

AXA

Funding accelerates the growth of Troy Medicare and its unique technology-enabled Medicare
Advantage plan designed to empower independent pharmacies and providers to care for
underserved communities in the US

November 17, 2020

Charlotte, NC. Troy Medicare, the pharmacy-powered, technology-driven Medicare Advantage
company, today announced it has raised a $10 million Series B round of funding led by AXA Venture
Partners, the global technology-focused venture capital firm. Sunwater Capital also participated in
the round.

With the support of investors, Troy will continue to expand its Medicare Advantage plan that provides
high-quality care and a superior patient experience to underserved communities via partnerships
with local, independent pharmacies and significant investment in technology.
“As the only Medicare Advantage company with deep relationships with independent pharmacies
and providers, we’re excited to bring AXA Venture Partners, with its understanding of healthcare
and technology, to the table as our first institutional investor,” said Flaviu Simihaian, CEO and Co-
Founder of Troy. “With this funding, we can continue to build out our model for a personal, hyperlocal
Medicare Advantage experience. Our partner pharmacists have a meaningful relationship with
their patients, and our plan leverages those touchpoints to improve the health of our members.”
“The Troy team is transforming care for Medicare Advantage beneficiaries, starting with North
Carolina,” said Manish Agarwal, General Partner at AXA Venture Partners. “Troy’s approach brings
a personalized, technology-enabled, local feel to care management and delivery for populations that
have been underserved by existing options in Medicare Advantage. We believe this model will
improve health outcomes and lower costs for these populations, and we’re excited to be a part of
the team.”

Troy Medicare launched in October 2018 with an innovative approach to Medicare Advantage that
leverages the local, independent pharmacy and technology to improve patient experience. With
100% transparent drug pricing, $0 generics at independent pharmacies, and no hidden fees for
pharmacies or providers, Troy offers a better Medicare Advantage plan for members and providers
alike. In 2021, Troy will expand its offering to dual-eligible Medicare beneficiaries and continue to
grow its team and expand its geographic footprint.

About Troy Medicare
Troy Medicare is a Medicare Advantage company based in Charlotte, North Carolina with a mission
to improve healthcare in each local community it serves. By empowering local providers and
pharmacies with world-class technology, Troy ensures that each member receives the best, tailored,
hyper-local care.

For more information on Troy Medicare, please visit http://www.troymedicare.com.

Contacts
Joey Shandley
press@troymedicare.com
704-275-8900 Ext. 111

About AXA Venture Partners (AVP)
AXA Venture Partners (AVP) is a global venture capital firm investing in high-growth, technologyenabled
companies. AVP has built, in less than five years, a unique investment platform specialized
in tech investments with $800 million of assets under management through three pillars of
investment expertise: early stage, growth stage, and fund of funds. To date, AVP has invested in
more than 45 companies and more than 20 funds. The AVP team operates globally with offices in
San Francisco, New York, London, Paris, and Hong Kong. Beyond investments, AVP provides
unique access to business development opportunities helping portfolio companies to scale globally
and accelerate their growth. More details here: www.axavp.com

Categories: News

Tags:

Centauri Health Solutions Adds Referral Management and Analytics Capabilities with Acquisition of Ivy Ventures, LLC

C

Deal continues year of Centauri’s growth in hospital revenue cycle optimization

Centauri Health Solutions (“Centauri”), an innovative healthcare technology and services company, announced today that it has acquired Ivy Ventures, LLC (“Ivy”), a Virginia-based healthcare growth solutions company focused on developing referral-driven service lines and improving care coordination. This addition expands Centauri’s comprehensive hospital solutions offerings, which already include Medicaid and Disability Eligibility and Enrollment, Out-of-State Medicaid Billing, and Revenue Cycle Analytics.

Founded in 2003, Ivy deploys an IP-enabled services model allowing major hospital networks to scale physician referral functions to grow referral driven service lines. Ivy utilizes a proprietary scheduling, analytics, and outreach platform to improve the experience and success rate of the referral process. Ivy’s data-driven process and insights deliver meaningful growth and improve user experience for their hospital and physician networks.

“Ivy is pleased to be joining a company with a similar foundation in leveraging technology and exceptional service to provide the best marketplace solutions,” said Roger Johnson, a founding partner of Ivy Ventures. “We look forward to offering Centauri’s unparalleled suite of revenue cycle optimization solutions to our long-term marquee clients to support their revenue growth in new ways.”

For Centauri, the addition of Ivy marks its fourth strategic acquisition in the hospital sector in less than 12 months. In December 2019, Centauri acquired Integrated Health Management Services, a Phoenix-based provider of revenue-cycle management services. Earlier this year, Centauri acquired HCFS, a Texas-based provider of self-pay management solutions, and AppRev, a Texas-based healthcare revenue cycle analytics company.

“Adding Ivy’s industry-leading referral management and analytics offerings to our growing portfolio expands the breadth and depth of our revenue cycle optimization solutions,” said Adam Miller, Centauri CEO and co-founder. “As we join forces with companies with complementary strengths, our goal is to provide our present and future health system clients with a full suite of services enabling them to streamline their vendor management processes and create efficiencies.”

The combined organization will be led by Miller, with Ivy’s founding partners, Johnson and Douglas Wetmore, and partners, Milan diPierro and Barrett Clark, joining Centauri’s management team.

The Ivy transaction was supported by Centauri’s lead investor, Abry Partners, and its other key investors, Silversmith Capital Partners and SV Health Investors. 7 Mile Advisors acted as the exclusive sellside advisor to Ivy. Weiss Brown LLP served as legal counsel to Centauri. Whiteford Taylor Preston was legal counsel to Ivy. Financial terms of the acquisition were not disclosed.

About Centauri Health Solutions

Centauri Health Solutions provides services to payors and providers across all healthcare programs, including Medicare, Medicaid, Commercial and Exchange. In partnership with our clients, we improve the lives and health outcomes of the members and patients we touch through compassionate outreach, sophisticated analytics, and data-driven solutions. Our services directly address complex problems such as uncompensated care within health systems; appropriate, risk-adjusted revenue for specialized sub-populations; and improve access to and quality of care measurement. Headquartered in Scottsdale, Ariz., Centauri Health Solutions employs 1,700 dedicated associates across the country. Centauri has ranked in the Top 500 on Inc. Magazine’s 2019 and 2020 Inc. 5000 lists of the fastest-growing private companies in the U.S. For more information, visit www.centaurihs.com.

About Abry Partners

Abry is one of the most experienced and successful sector-focused private equity investment firms in North America. Since their founding in 1989, the firm has completed over $82.0 billion of leveraged transactions and other private equity or preferred equity placements. Currently, the firm manages over $5.0 billion of capital across their active funds. For more information on Abry, please visit www.abry.com.

About Silversmith Capital Partners

Founded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $2.0 billion of capital under management. Silversmith’s mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. Representative investments include ActiveCampaign, Appfire, Centauri Health Solutions, DistroKid, Impact, LifeStance Health, MediQuant, Panalgo, Unily, Validity, and Webflow. The partners have over 75 years of collective investing experience and have served on the boards of numerous successful growth companies including ABILITY Network, Archer Technologies, Dealer.com, Liazon, Liberty Dialysis, MedHOK, Net Health, Passport Health, SurveyMonkey, and Wrike. For more information about Silversmith, please visit www.silversmithcapital.com.

About SV Health Investors

SV Health Investors is a leading healthcare fund manager investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions and sectors, with expertise spanning healthcare services / technology, medical products, biotechnology, dementia and public equities. With approximately $2.2B in assets under management and offices in Boston and London, SV has built an extensive network of investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies, with more than 75 of these having achieved successful acquisitions or IPOs. For more information, please visit www.svhealthinvestors.com.

Contacts

Gretchen Adin | Director, Marketing & Communications

Gretchen.Adin@centaurihs.com | 480.418.3447

With new CEO on board, Germany’s Vibalogics lays out $150M for Boston viral vector site

With the race for COVID-19 vaccines heating up and the cell and gene therapy market booming, contract manufacturers in the viral vector space are quickly bulking up to meet demand. Hoping to ride that wave, Germany’s Vibalogics is planting its flag in the U.S. with a new leader in place.

Months after appointing a new global CEO, German contract manufacturer Vibalogics will shell out $150 million to build out a 110,000-square-foot “virotherapy” facility near Boston set to come online in the second half of 2021, the company said Wednesday.

The new facility will be built out over three years and eventually house 2,000 liters of bioreactor capacity, dedicated to producing clinical and commercial-stage oncolytic viruses and viral vectors used in vaccines and cell and gene therapies, Vibalogics said in a release. The work may include manufacturing for Johnson & Johnson’s COVID-19 vaccine candidate under a deal the partners inked in May.

The site will initially employ 100 workers and scale up to 250 over four years, Vibalogics said.

With that toehold in the U.S., Vibalogics hopes to build its global viral offerings under the leadership of managing director Stefan Beyer and CEO Tom Hochuli, who came over from Lonza Houston in September.

During his two-year stint at Lonza’s 300,000-square-foot facility in that city, Hochuli supervised a workforce expansion of around 400 employees and had a chance to get intimate with the cell and gene therapy space. In the early days in his new role at Vibalogics, Hochuli was tasked with overseeing the search for the new U.S. site.

Vibalogics also operates a clinical-stage manufacturing facility in Cuxhaven, Germany, the company said.

Vibalogics was the target of a buyout by private equity firm Ampersand Capital in May 2019 that Beyer said allowed the CDMO to focus more on its life sciences offerings after years of wallowing in a diversified business that had tentacles in the poultry and meat industries.

“Ampersand jumped on board and has realized the great potential we have developed during the last four to five years,” Beyer said. “It was really great that we have been able to continue with our strategy by convincing (them) to look into biologics.”

Vibalogics hopes to capture a bustling cell and gene therapy market on top of its work in COVID-19 vaccines. Manufacturing of those therapies is notoriously expensive and time-consuming, and some drugmakers in the field have outsourced that work to contract manufacturers to help meet demand.

Categories: News

Tags:

Drug discovery CRO MercachemSyncom adds biology services through acquisition

GIlde Healthcare

Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje (Sweden). The acquisition of Admescope allows MercachemSyncom to significantly expand its service offering with tailor-made-in-vitro ADME-tox studies for pre-clinical and early clinical R&D projects. MercachemSyncom expects seamless integration with its existing medicinal, synthetic and development chemistry capabilities.

Admescope, founded in 2011, brings world-class expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Its experienced scientific and management teams have executed ADME-Tox studies for pharma and biotech clients across the world.

Eelco Ebbers, CEO of MercachemSyncom, commented,

“We are pleased to welcome our new colleagues fom Admescope. The high quality, innovative and client-centric ADME-Tox services of Admescope represent a perfect, complimentary match with our organization. The addition of Admescope to MercachemSyncom marks an exciting year for our company. The expansion of our cGMP manufacturing apabilities via the acquisition of our Weert site at the beginning of the year has had an extremely positive effect on our business and client base, resulting in a record year in terms of medicinal and synthetic chemistry services.”

Rafael Natanek, Partner at Gilde Healthcare, commented,

“This is the third acquisition since our investment in MercachemSyncom, executing our active buy-and-build agenda to complement the strong organic growth of the company. Admescope adds specialized biology services to MercachemSyncom and enables integrated contract research services from hit-finding to Phase 2a. Combined with the acquisition of Alcami Weert last year, Admescope further solidifies MercachemSyncom’s position as the premier mid-sized drug discovery CRO in Europe.”

About MercachemSyncom

MercachemSyncom is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, ADME-Tox, early drug substance development, and GMP production services to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom offers integrated drug-discovery services from hit to clinic. Working for many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high-quality products and services and its unprecedented problem-solving capabilities. For more information, visit the company’s website at www.mercachemsyncom.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Bridgepoint Growth to partner with Swedish medical dermatology group Diagnostiskt Centrum Hud

Bridgepoint

Diagnostiskt Centrum Hud (‘DCH’), the leading provider of medical dermatology services in Sweden, has partnered with Bridgepoint Growth to further support the company’s expansion.

Headquartered in Stockholm, DCH was founded in 2012 by its CEO and three dermatologists, combining their business and medical backgrounds to address the untapped demand for high quality medical dermatology treatments. The market is underpinned by structural growth drivers, including an aging population and an increase in the incidence of skin diseases such as skin cancer. s. DCH focuses on treating melanoma, psoriasis and other severe dermatology conditions.

Today DCH operates six clinics across four Swedish cities and is the clear market leader in Sweden. DCH is a high-quality platform well placed for future growth in the fragmented dermatology markets across Northern Europe.

“We are excited to partner with Bridgepoint in the next stage of our expansion and further build the best dermatology provider across the Nordics together with our colleagues,“ said Philip Jerlmyr, CEO DCH.

”We are very impressed by DCH’s successful expansion to-date creating the leading dermatology provider focused on clinical excellence and high customer satisfaction thanks to its having the best dermatologists. We look forward to supporting the DCH team in its next phase of expansion” added Ann Dahlman, partner at Bridgepoint Growth responsible for its investment activities in the Nordic region.

Advisors involved in the transaction were:

For Bridgepoint: Vinge (legal), KPMG (financial and tax), Roland Berger (commercial)

For management: AG Advokat (legal), GT (financial and tax)

Categories: News

Tags:

HealthComp Announces Partnership with New Mountain Capital

New Mountain Capital

Investment Firm to Support Leading Independent Third-Party Administrator’s Client Offerings and Growth 


FRESNO, Calif. and NEW YORK – November 9, 2020 – HealthComp Holding Company LLC (“HealthComp” or “the Company”), a leading independent Third Party Administrator (TPA) of healthcare benefits for self-funded employers, announced today that the Company has partnered with New Mountain Capital, a leading growth-oriented investment firm with $28 billion in assets under management.

Founded in 1994 and headquartered in Fresno, California, HealthComp is the largest independent Third-Party Administrator (TPA) of healthcare benefits in the U.S., serving more than 400,000 members in the self-funded employer industry. The Company offers best in class technology for healthcare benefits administration, payment integrity and care management services to address the “dual mandate” in the U.S. healthcare system: reducing costs and improving clinical outcomes and experience for employees. As part of the transaction, HealthComp’s CEO and management team will remain in place and invested in the company.

“HealthComp is dedicated to transforming benefits management into an experience that employees and employers love, and we are excited to partner with New Mountain Capital to recognize our full potential as a market leader,” said HealthComp CEO Jose Rivero. “We expect to benefit from the team’s deep sector knowledge, growth-oriented philosophy, and highly relevant industry relationships, to set the stage for our continued growth acceleration. We thank Alpine Investors for their fantastic partnership, and we look forward to continuing to build the HealthComp platform with the support and strategic guidance of New Mountain Capital.”

“HealthComp’s strong track record of cost containment and unwavering commitment to improving clinical outcomes for employee populations creates the opportunity to build a leading, scaled platform in an attractive, growing market with significant upside potential,” said Matt Holt, Managing Director and President, Private Equity at New Mountain Capital. “New Mountain Capital’s deep experience in healthcare cost containment will allow HealthComp to capitalize on an unparalleled opportunity to leverage institutional knowledge to drive business building and increase value for customers.”

Kyle Peterson, Managing Director at New Mountain Capital, said, “HealthComp’s scale, track-record, and market reputation make it the ideal platform for the development of a next generation TPA model. We see significant opportunity to leverage New Mountain’s capabilities in data and analytics to drive core platform competencies and a unique commercial strategy. Further investment in an already robust technology platform with the expansion of cost and clinical management capabilities will drive best-in-class cost containment and employee experience for self-funded employers and their employees.”

TripleTree LLC served as exclusive financial advisor and Wilson Sonsini served as legal counsel to HealthComp in the transaction. Ropes & Gray LLP provided legal counsel to New Mountain.


About HealthComp 

For more than 25 years, HealthComp has been dedicated to transforming benefits administration. Bringing together concierge-level service, operational excellence, powerful analytics and cost management, HealthComp has built a solution that integrates seamlessly with any benefits ecosystem. HealthComp has offices in California, Illinois, West Virginia and Pennsylvania. Visit healthcomp.com.


About New Mountain Capital 

New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with $28 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com 


Press Release Contacts

HealthComp 

Joy Scott
Phone: 818.610.0270
joy@scottpublicrelations.com

New Mountain Capital 

Dana Gorman / Claire Walsh
Abernathy MacGregor
(212) 371-5999
dtg@abmac.com / cw@abmac.com

Categories: News

Tags:

Alpine’s HealthComp Announces Partnership With New Mountain Capital

Alpine

SAN FRANCISCO–(BUSINESS WIRE)–Alpine Investors (“Alpine”), a middle-market private equity firm that focuses on investing in people to build enduring companies, today announced that HealthComp Holding Company, LLC (“HealthComp”), a leading independent Third Party Administrator (TPA), is partnering with New Mountain Capital, a leading growth-oriented investment firm with $28 billion in assets under management. As part of the transaction, Alpine is exiting its investment in HealthComp.

Founded in 1994 and headquartered in Fresno, California, HealthComp is the largest independent Third-Party Administrator (TPA) of healthcare benefits in the U.S., serving more than 400,000 members in the self-funded employer industry. The Company offers best in class technology for healthcare benefits administration, payment integrity and care management services to address the “dual mandate” in the U.S. healthcare system: reducing costs and improving clinical outcomes and experience for employees. As part of the transaction, HealthComp’s CEO and management team will remain in place and invested in the company.

“Through our partnership with Alpine, HealthComp has been able to address the ‘dual mandate’ in U.S. healthcare of reducing costs and improving the member experience,” said Jose Rivero, CEO at HealthComp. “We thank Alpine Investors for their fantastic partnership, and we look forward to continuing to build the HealthComp platform with the support and strategic guidance of New Mountain Capital.”

“We are proud of what we have accomplished with HealthComp over the past four years. Jose’s people-driven leadership, innovation, and focus on operational excellence have created the leading independent TPA in the country. We’re excited to see HealthComp’s growth continue as a result of its partnership with New Mountain Capital,” said Will Adams, Partner at Alpine Investors.

TripleTree, LLC served as the exclusive financial advisor to HealthComp for the transaction and Wilson Sonsini Goodrich & Rosati served as legal counsel.

About Alpine Investors

Alpine Investors is a people-driven private equity firm that is committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in middle-market companies in the software and services industries. Its PeopleFirst™ strategy includes a CEO-in-Residence program which allows Alpine to bring proven leadership to situations where additional or new management is needed post-transaction. Alpine is currently investing out of its $1 billion seventh fund. For more information, visit http://www.alpineinvestors.com.

About HealthComp Holding Company, LLC

For more than 25 years, HealthComp has been dedicated to transforming benefits administration. Bringing together concierge-level service, operational excellence, powerful analytics and cost management, HealthComp has built a solution that integrates seamlessly with any benefits ecosystem. HealthComp has offices in California, Illinois, West Virginia and Pennsylvania. For more information, visit healthcomp.com.

Categories: News

Tags: